Traduction de «focusing on diseases » (Néerlandais → Français) :

TERMINOLOGIE

central-core-disease | congenitale spierdystrofie | NNO | congenitale spierdystrofie | met specifieke morfologische-afwijkingen van spiervezel | fibre-type disproportion | minicore disease | multicore disease | myopathie | myotubulair (centronucleair) | myopathie | nemaline lichaampjes
Disproportion des types de fibres Dystrophie musculaire congénitale:SAI | avec anomalies morphologiques spécifiques des fibres musculaires | Myopathie:à axe central | à bâtonnets [némaline] | de type: mini-core | multi-core | myotubulaire (centro-nucléaire)

ziekte van Franklin | gamma heavy chain disease | Mmu heavy chain disease
Maladie de Franklin

ADTKD-UMOD - UMOD-related autosomal dominant tubulointerstitial kidney disease
néphropathie tubulo-interstitielle autosomique dominante associée à UMOD

ADTKD-MUC1 - MUC1-related autosomal dominant tubulointerstitial kidney disease
néphropathie tubulo-intersitielle autosomique dominante associée à MUC1

Border disease-virus
virus Border disease

Borna disease-virus
virus Borna disease

AIED - Åland Islands eye disease
maladie ophtalmique des îles Åland

ADPCLD - autosomal dominant polycystic liver disease
polykystose hépatique isolée

bovien mucosal disease-virus
virus Bovine mucosal disease

Nairobi sheep disease-virus
virus Nairobi sheep disease

TRADUCTIONS EN CONTEXTE

FoldRx is a development and discovery company focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding and aggregation (amyloidosis) based on the pioneer work of its scientific founders, Jeffery Kelly (The Scripps Research Institute) and Susan Lindquist (Whitehead Institute).
folding and its platform for drug and target discovery, the company is building a pipeline, initially for neurodegenerative and respiratory conditions. FoldRx’s pipeline includes a program in advanced clinical development to treat genetic neurologic and cardiovascular disorders, Transthyretin (TTR) Amyloid Polyneuropathy (ATTR-PN) and TTR Amyloid Cardiomyopathy (ATTR-CM), and a discovery program in cystic fibrosis, Parkinson’s, and Huntington’s disease based on its broad, proprietary, yeast-based drug discovery platform.

FoldRx Focused on First-in-Class, Disease-Modifying, Oral Therapeutics to Treat Diseases Caused by Protein Misfolding - -
FoldRx Focused on First-in-Class, Disease-Modifying, Oral Therapeutics to Treat Diseases Caused by Protein Misfolding

Therefore a future study focusing on the proportion of thyroid cancer in surgery for nodular disease (with exclusion of surgery for thyrotoxicosis only) as well as on the proportion of thyroid cancer in total thyroidectomy and lobectomy separately would be of value. In line with the finding of more preoperative FNAC in the Flemish and the Brussels-Capital Region, the proportion of surgical patients with only a
Therefore a future study focusing on the proportion of thyroid cancer in surgery for nodular disease (with exclusion of surgery for thyrotoxicosis only) as well as on the proportion of thyroid cancer in total thyroidectomy and lobectomy separately would be of value.

2011: Rooke TW, Hirsch AT, Misra S et al. 2011 ACCF/AHA Focused update of the guideline for the management of patients with peripheral artery disease.
Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/AHA 2005 Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric and abdominal aortic): Executive summary.

This initiative, announced in April 2010, will create three national specialty businesses focused on multiple sclerosis, respiratory diseases and neuroscience to complement the existing Oncology business unit.
Annoncé en avril 2010, ce projet créera trois secteurs d’activité nationaux spécialisés respectivement dans la sclérose en plaques, les maladies respiratoires et les neuropathies, complétant ainsi Oncologie, l’unité d’affaires existante.

Novartis is helping patients in the developing world through key initiatives focused on neglected diseases, especially malaria, leprosy, dengue fever and treatment-resistant tuberculosis.
Novartis aide les malades des pays en voie de développement par le biais de projets importants centrés sur des maladies négligées, en particulier le paludisme, la lèpre, la fièvre de dengue et la tuberculose résistant aux traitements.

These priorities are: (1) extending our lead in innovation by focusing on diseases with significant unmet need and delivering positive patient outcomes; (2) accelerating growth across all divisions through tailored commercial models that leverage our broad portfolio and expansion in emerging markets; and (3) driving productivity across our business to continue improving margins and reinvesting for future growth.
Ces priorités sont: 1) augmenter notre avance dans l’innovation en nous concentrant sur des besoins non satisfaits des soins de santé et sur l'efficacité des médicaments pour les patients, 2) accélérer notre croissance dans toutes les divisions, par le biais de modèles commerciaux taillés sur mesure qui tirent le meilleur parti de notre vaste portefeuille, et nous étendre dans les marchés émergents et 3) accroître la productivité dans toutes nos activités afin de continuer d’améliorer nos marges et de réinvestir dans notre croissance future.

Consistent with this focused research strategy, new Phase II data demonstrates that ACZ885, currently marketed as Ilaris for the rare disease cryopyrin-associated periodic syndrome (CAPS), provided highly statistically significant risk reduction of acute flares in gout patients compared to the anti-inflammatory standard of care.
Cette approche stratégique est illustrée par ACZ885, un médicament actuellement commercialisé sous la marque Ilaris pour traiter le syndrome périodique associé à la cryopirine (CAPS), une maladie rare. De nouveaux résultats d’une étude de phase II ont montré que ce médicament induisait une réduction importante, hautement significative sur le plan statistique, du risque de crises aiguës de goutte par comparaison avec le traitement anti-inflammatoire standard.